Advances in Therapy

, 25:787 | Cite as

Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC

  • Po Yang
  • Minghui Liang
  • Yingxun Zhang
  • Baozhong Shen
Original Research

Abstract

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death worldwide and there is a clear need for further treatment options. In this study, we assessed the efficacy of a combination of lentinan (a fungal extract), transcatheter arterial chemoembolisation (TACE) and radiofrequency ablation (RFA) in HCC patients.

Methods

Seventy-eight patients with HCC confirmed by pathology and iconographical checks were used in this study. A total of 136 tumours with a mean diameter of 6.5 cm were detected (standard deviation [SD]±0.7). Subjects were divided into four groups, receiving either TACE only, RFA only, RFA and TACE, or the combination group — receiving lentinan, RFA and TACE.

Results

The tumour necrosis was significantly higher in the combination group (88.6%), compared to the TACE group (37.5%), the RFA group (47.8%) and the TACE/RFA group (60.3%; P<0.05). The tumour recurrence rate was significantly lower in the combination group (17.8%), compared to the TACE group (45.8%), the RFA group (34.7%) and the TACE/RFA group (29.0%; P<0.05). Finally, mean survival duration was significantly higher in the combination group (28.2 months; P<0.05).

Conclusion

Combination therapy involving lentinan, RFA and TACE was beneficial in terms of increasing mean survival duration, tumour necrosis and reducing the recurrence rate. Lentinan may therefore be of benefit to HCC patients.

Keywords

hepatocellular carcinoma lentinan radiofrequency ablation transcatheter hepatic arterial chemoembolisation 

References

  1. 1.
    Höpfner M, Huether A, Sutter A, Baradari V, Schuppan D, Scherübl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:1435–1448.PubMedCrossRefGoogle Scholar
  2. 2.
    Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg. 2006;10:761–780.PubMedCrossRefGoogle Scholar
  3. 3.
    Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:1–8.CrossRefGoogle Scholar
  4. 4.
    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096.PubMedGoogle Scholar
  5. 5.
    Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–1150.PubMedCrossRefGoogle Scholar
  6. 6.
    Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302–309.PubMedGoogle Scholar
  7. 7.
    Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intraarterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194:165–170.PubMedGoogle Scholar
  8. 8.
    De Mitri MS, Puossin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413–415.PubMedCrossRefGoogle Scholar
  9. 9.
    Liapi E, Geschwind JFH. Transcatheter arterial chemoembolisation (TACE) for HCC’ classic concepts and future evolution. Eur Oncological Dis. 2006;1:47–52.Google Scholar
  10. 10.
    Tsukuma H, Hiyami T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801.PubMedCrossRefGoogle Scholar
  11. 11.
    Frazer C. Imaging of hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:750–756.PubMedCrossRefGoogle Scholar
  12. 12.
    Sugimori K, Nozawa A, Morimoto M, et al. Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge: results in a pig model. J Vasc Interv Radiol. 2005;16:849–856.PubMedGoogle Scholar
  13. 13.
    Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumors. Eur J Gastroenterol Hepatol. 2000;12:151–157.PubMedCrossRefGoogle Scholar
  14. 14.
    Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D. Treatment of metastatic glucagonoma to the liver: case report and literature review. Ital J Gastroenterol Hepatol. 1999;31:308–312.PubMedGoogle Scholar
  15. 15.
    Bizollon T, Rode A, Bancel B, et al. Diagnostic value and tolerance of lipiodolcomputed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol. 1998;28:491–496.PubMedCrossRefGoogle Scholar
  16. 16.
    Wu P, Zhang F, Zhao M, et al. Combination of transcatheter arterial chemoembolization and CT-guided radiofrequency ablation in treating advanced hepatocellular carcinoma. Chin J Radiology (Chin). 2003;37:901–904.Google Scholar
  17. 17.
    Zhang L, Cui Z, Zhao Q, et al. RFA combined with TACE and ethanol injection for unresectable hepatic carcinoma. Chin J General Surg (Chin). 2002;40:826–829.Google Scholar
  18. 18.
    Lindequist U, Niedermeyer TH, Jülich WD. The pharmacological potential of mushrooms. eCAM. 2005;2:285–299.PubMedGoogle Scholar
  19. 19.
    Wasser SP, Weis AL. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (review). Int J Med Mushrooms. 1999;1:31–62.Google Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  • Po Yang
    • 1
  • Minghui Liang
    • 2
  • Yingxun Zhang
    • 3
  • Baozhong Shen
    • 4
  1. 1.Invasive Technology DepartmentFourth Affiliated Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Medical Technology DepartmentQiqihar Medical UniversityQiqiharChina
  3. 3.Nuclear Medicine DepartmentFourth Affiliated Hospital of Harbin Medical UniversityHarbinChina
  4. 4.Medical Imaging DepartmentFourth Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations